Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide

References

• Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007;CD004421.
   PubMed Web of Science ®Google Scholar
• Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, . Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer 2006;106:2337–44.
   PubMed Web of Science ®Google Scholar
• De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E, . Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 2008;26:44–53.
   PubMed Web of Science ®Google Scholar
• Estevez LG, Munoz M, Alvarez I, Fernandez Y, Garcia-Mata J, Ruiz-Borrego M, . Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. Cancer Treat Rev 2007;33:474–83.
   PubMed Web of Science ®Google Scholar
• Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, . Chemotherapy-induced peripheral neuropathies: From clinical relevance to preclinical evidence. Expert Opin Drug Saf 2011;10:407–17.
   PubMed Web of Science ®Google Scholar
• Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy- induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008;15:3081–94.
   PubMed Web of Science ®Google Scholar
• Eckhoff L, Nielsen M, Moeller S, Knoop A. TAXTOX: – A retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol 2011;50:1075–82.
   PubMed Web of Science ®Google Scholar
• Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 2009;302:1985–92.
   PubMed Web of Science ®Google Scholar
• Andersen KG, Kehlet H. Persistent pain after breast cancer treatment: A critical review of risk factors and strategies for prevention. J Pain 2011;12:725–46.
   PubMed Web of Science ®Google Scholar
• Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group – DBCG: History, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol 2008;47:497–505.
   PubMed Web of Science ®Google Scholar
• Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, . The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008;47:506–24.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357–65.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569–83.
   PubMed Web of Science ®Google Scholar
• Gartner R, Jensen MB, Kronborg L, Ewertz M, Kehlet H, Kroman N. Self-reported arm-lymphedema and functional impairment after breast cancer treatment – a nationwide study of prevalence and associated factors. Breast 2010; 19:506–15.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, . Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9–19.
   PubMed Web of Science ®Google Scholar
• Schwartz CE, Sprangers MA. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med 1999;48:1531–48.
   PubMed Web of Science ®Google Scholar
• Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, . Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006;17:1205–12.
   PubMed Web of Science ®Google Scholar
• Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, . Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302–13.
   PubMed Web of Science ®Google Scholar
• Martin M, Segui MA, Anton A, Ruiz A, Ramos M, Adrover E, . Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 2010;363:2200–10.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, . Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011;125:767–74.
   PubMed Web of Science ®Google Scholar
• Persohn E, Canta A, Schoepfer S, Traebert M, Mueller L, Gilardini A, . Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 2005;41:1460–6.
   PubMed Web of Science ®Google Scholar
• Andersen KG, Gartner R, Kroman N, Flyger H, Kehlet H. Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: A randomized trial. Breast 2012;21:46–9.
   Google Scholar